-
ProKidney NasdaqCM:PROK ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Location: 2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, United States | Website: https://prokidney.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.148B
Cash
328.5M
Avg Qtr Burn
-30.32M
Short % of Float
20.01%
Insider Ownership
30.05%
Institutional Own.
41.84%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes | Phase 3 Update | |
Rilparencel (REACT®) Details Chronic kidney disease, Diabetes | Phase 2 Data readout | |
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes | Phase 2 Update | |
Rilparencel (REACT®) Details Chronic kidney disease, Type 2 diabetes | Failed Discontinued |